Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 341

The DOI matches its Crossref record; 279 of the 279 references it cites were found in a registry or an index.

Therapeutic targeting of EPH receptors and their ligands

Boyd, Andrew W., Bartlett, Perry F., Lackmann, Martin·2014·Nature Reviews Drug Discovery

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd4175

Cites

279 of 279 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 279 references

Research works printed but not linked: 26

  1. Marquardt, T. et al. Coexpressed EphA receptors and ephrin-A ligands mediate opposing actions on growth cone navigation from distinct membrane domains. Cell 121, 127–139 (2005). · doi:10.1016/j.cell.2005.01.020
  2. Gu, C. & Park, S. The EphA8 receptor regulates integrin activity through p110γ phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol. Cell. Biol. 21, 4579–4597 (2001). · doi:10.1128/mcb.21.14.4579-4597.2001
  3. Wimmer-Kleikamp, S. H. et al. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112, 721–732 (2008). · doi:10.1182/blood-2007-11-121681
  4. Dopeso, H. et al. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res. 69, 7430–7438 (2009). · doi:10.1158/0008-5472.can-09-0706
  5. Hagey, A. et al. A recombinant antibody to EphA3 for the treatment of hematologic malignancies: research update and interim Phase 1 study results. Blood (ASH Annual Meeting Abstracts) 118, 4893 (2011).
  6. Dawson, D. W. et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 26, 4243–4252 (2007). · doi:10.1038/sj.onc.1210211
  7. Wang, J. et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum. Pathol. 38, 1649–1656 (2007). · doi:10.1016/j.humpath.2007.01.030
  8. Guan, M., Xu, C., Zhang, F. & Ye, C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int. J. Cancer 124, 88–94 (2009). · doi:10.1002/ijc.23890
  9. Nievergall, E., Saunders, T. & Lackmann, M. Targeting of EPH receptor tyrosine kinases for anticancer therapy. Crit. Rev. Oncog. 17, 211–232 (2012). · doi:10.1615/critrevoncog.v17.i2.60
  10. Palath, V. et al. A recombinant antibody to EphA3 with pro-apoptotic and enhanced ADCC activity against various hematologic malignancies shows selective inhibition of colony formation from long-term culture-initiating cells (LTC-ICs) in primary leukemia samples. Blood (ASH Annual Meeting Abstracts) 116, 2897 (2010).
  11. Heroult, M. et al. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2. Mol. Cancer Res. 8, 1297–1309 (2010). · doi:10.1158/1541-7786.mcr-09-0453
  12. Scehnet, J. S. et al. The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood 113, 254–263 (2009). · doi:10.1182/blood-2008-02-140020
  13. Noblitt, L. W., Bangari, D. S., Shukla, S., Mohammed, S. & Mittal, S. K. Immunocompetent mouse model of breast cancer for preclinical testing of EphA2-targeted therapy. Cancer Gene Ther. 12, 46–53 (2005). · doi:10.1038/sj.cgt.7700763
  14. Wakelee, H. A. et al. A phase I dose-escalation and pharmacokinetic (PK) study of a novel spectrum selective kinase inhibitor, XL647, in patients with advanced solid malignancies (ASM). J. Clin. Oncol. 24, Abstr. 3044 (2006). · doi:10.1200/jco.2006.24.18_suppl.3044
  15. Bardelle, C. et al. Inhibitors of the tyrosine kinase EphB4. Part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg. Med. Chem. Lett. 18, 2776–2780 (2008). · doi:10.1016/j.bmcl.2008.04.015
  16. Jin, M. et al. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci. 99, 1656–1662 (2008). · doi:10.1111/j.1349-7006.2008.00866.x
  17. Irizarry-Ramirez, M. et al. Upregulation of EphA3 receptor after spinal cord injury. J. Neurotrauma 22, 929–935 (2005). · doi:10.1089/neu.2005.22.929
  18. Arocho, L. C. et al. Expression profile and role of EphrinA1 ligand after spinal cord injury. Cell. Mol. Neurobiol. 31, 1057–1069 (2011). · doi:10.1007/s10571-011-9705-2
  19. Lickliter, J. D., Smith, F. M., Olsson, J. E., Mackwell, K. L. & Boyd, A. W. Embryonic stem cells express multiple Eph-subfamily receptor tyrosine kinases. Proc. Natl Acad. Sci. USA 93, 145–150 (1996). · doi:10.1073/pnas.93.1.145
  20. Lazarova, P. et al. Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood. Int. J. Immunopathol. Pharmacol. 19, 49–56 (2006). · doi:10.1177/205873920601900105
  21. Luo, H., Yu, G., Tremblay, J. & Wu, J. EphB6-null mutation results in compromised T cell function. J. Clin. Invest. 114, 1762–1773 (2004). · doi:10.1172/jci21846
  22. Baldwin, C. et al. Upregulation of EphA2 during in vivo and in vitro renal ischemia-reperfusion injury: role of Src kinases. Am. J. Physiol. Renal Physiol. 291, F960–F971 (2006). · doi:10.1152/ajprenal.00020.2006
  23. Cercone, M. A., Schroeder, W., Schomberg, S. & Carpenter, T. C. EphA2 receptor mediates increased vascular permeability in lung injury due to viral infection and hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L856–L863 (2009). · doi:10.1152/ajplung.00118.2009
  24. Tournoij, E. et al. The platelet P2Y12 receptor contributes to granule secretion through Ephrin A4 receptor. Platelets 23, 617–625 (2012). · doi:10.3109/09537104.2011.645924
  25. Hayashi, S., Asahara, T., Masuda, H., Isner, J. M. & Losordo, D. W. Functional ephrin-B2 expression for promotive interaction between arterial and venous vessels in postnatal neovascularization. Circulation 111, 2210–2218 (2005). · doi:10.1161/01.cir.0000163566.07427.73
  26. Zhao, X. et al. Vaccines targeting tumor blood vessel antigens promote CD8+ T cell-dependent tumor eradication or dormancy in HLA-A2 transgenic mice. J. Immunol. 188, 1782–1788 (2012). · doi:10.4049/jimmunol.1101644

Cited by

See all 341

Metadata

Authors
Boyd, A. W., Bartlett, P. F., & Lackmann, M.
Venue
Nature Reviews Drug Discovery
Published
2013-12-31
Volume
13
Issue
1
Pages
39-62
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2038385234
Cited by
341
References
279
FWCI
2.14
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic targeting of EPH receptors and their ligands. https://app.cochat.ai/papers/10.1038/nrd4175
The paper
Boyd, A. W., Bartlett, P. F., & Lackmann, M. (2014). Therapeutic targeting of EPH receptors and their ligands. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd4175

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.